Our research demonstrates that, in breast cancers, CK2 signaling is associated with elevated ER expression and tamoxifen resistance, and that pharmacological inhibition with CX can disrupt ERα overexpression and, therefore, cancer cell viability. The gene discussed is ESR1; the disease is breast cancer.